
Jann-Yuan Wang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8811506/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Acute-on-chronic kidney injury at hospital discharge is associated with long-term dialysis and mortality. Kidney International, 2011, 80, 1222-1230.	2.6	163
2	The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis. Lancet, The, 2020, 395, 973-984.	6.3	160
3	Update on tuberculosis biomarkers: From correlates of risk, to correlates of active disease and of cure from disease. Respirology, 2018, 23, 455-466.	1.3	150
4	Revisiting tuberculous pleurisy: pleural fluid characteristics and diagnostic yield of mycobacterial culture in an endemic area. Thorax, 2012, 67, 822-827.	2.7	140
5	Risk factors of early redialysis after weaning from postoperative acute renal replacement therapy. Intensive Care Medicine, 2008, 34, 101-108.	3.9	124
6	Disseminated Tuberculosis. Medicine (United States), 2007, 86, 39-46.	0.4	119
7	Metformin Use Reverses the Increased Mortality Associated With Diabetes Mellitus During Tuberculosis Treatment. Clinical Infectious Diseases, 2018, 66, 198-205.	2.9	115
8	Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. Journal of Antimicrobial Chemotherapy, 2007, 59, 860-865.	1.3	112
9	Tuberculosis mortality: patient characteristics and causes. BMC Infectious Diseases, 2014, 14, 5.	1.3	91
10	A simple gold nanoparticle probes assay for identification of Mycobacterium tuberculosis and Mycobacterium tuberculosis complex from clinical specimens. Molecular and Cellular Probes, 2009, 23, 240-246.	0.9	90
11	Pulmonary Tuberculosis and Delay in Anti-Tuberculous Treatment Are Important Risk Factors for Chronic Obstructive Pulmonary Disease. PLoS ONE, 2012, 7, e37978.	1.1	89
12	Outcome and prognostic factors for patients with non-small-cell lung cancer and severe radiation pneumonitis. International Journal of Radiation Oncology Biology Physics, 2002, 54, 735-741.	0.4	85
13	Diabetes mellitus and latent tuberculosis infection: a systemic review and meta-analysis. Clinical Infectious Diseases, 2017, 64, ciw836.	2.9	84
14	Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respiratory Medicine,the, 2018, 6, 265-275.	5.2	80
15	Pneumothorax in the ICU. Chest, 2002, 122, 678-683.	0.4	79
16	Necrotizing pneumococcal pneumonia in children: The role of pulmonary gangrene. Pediatric Pulmonology, 2006, 41, 623-629.	1.0	71
17	Risk factors of hepatitis during Anti-tuberculous treatment and implications of hepatitis virus load. Journal of Infection, 2011, 62, 448-455.	1.7	70
18	Performance Assessment of a Nested-PCR Assay (the RAPID BAP-MTB) and the BD ProbeTec ET System for Detection of Mycobacterium tuberculosis in Clinical Specimens. Journal of Clinical Microbiology, 2004, 42, 4599-4603.	1.8	69

#	Article	IF	CITATIONS
19	Risk factors for pulmonary tuberculosis in patients with chronic obstructive airway disease in Taiwan: a nationwide cohort study. BMC Infectious Diseases, 2013, 13, 194.	1.3	69
20	Diagnosis of Tuberculosis by an Enzyme-Linked Immunospot Assay for Interferon-Î ³ . Emerging Infectious Diseases, 2007, 13, 553-558.	2.0	63
21	Evaluating pleural ADA, ADA2, IFN-γ and IGRA for diagnosing tuberculous pleurisy. Journal of Infection, 2013, 67, 294-302.	1.7	61
22	Optimal Duration of Anti-TB Treatment in Patients With Diabetes. Chest, 2015, 147, 520-528.	0.4	60
23	Epidemiology and Predictors of NTM Pulmonary Infection in Taiwan - a Retrospective, Five-Year Multicenter Study. Scientific Reports, 2017, 7, 16300.	1.6	60
24	Prediction of the Tuberculosis Reinfection Proportion from the Local Incidence. Journal of Infectious Diseases, 2007, 196, 281-288.	1.9	54
25	Mycobacterium tuberculosis and polymorphonuclear pleural effusion: Incidence and clinical pointers. Respiratory Medicine, 2009, 103, 820-826.	1.3	54
26	Factors influencing time to smear conversion in patients with smearâ€positive pulmonary tuberculosis. Respirology, 2009, 14, 1012-1019.	1.3	53
27	Acute kidney injury due to anti-tuberculosis drugs: a five-year experience in an aging population. BMC Infectious Diseases, 2014, 14, 23.	1.3	53
28	Microbiological Persistence in Patients With Mycobacterium avium Complex Lung Disease: The Predictors and the Impact on Radiographic Progression. Clinical Infectious Diseases, 2017, 65, 927-934.	2.9	52
29	Clinical Characteristics and Prognosis of Nontuberculous Mycobacterial Lung Disease with Different Radiographic Patterns. Lung, 2011, 189, 467-474.	1.4	50
30	Direct and Simultaneous Identification of Mycobacterium tuberculosis complex (MTBC) and Mycobacterium tuberculosis (MTB) by Rapid Multiplex nested PCR-ICT assay. Journal of Microbiological Methods, 2006, 66, 440-448.	0.7	46
31	Trends and predictors of changes in pulmonary function after treatment for pulmonary tuberculosis. Clinics, 2011, 66, 549-556.	0.6	46
32	Effect of ventilation improvement during a tuberculosis outbreak in underventilated university buildings. Indoor Air, 2020, 30, 422-432.	2.0	46
33	Treatment outcome of patients with isoniazid mono-resistant tuberculosis. Clinical Microbiology and Infection, 2015, 21, 59-68.	2.8	43
34	Diffuse pulmonary infiltrates after bone marrow transplantation: the role of open lung biopsy. Annals of Thoracic Surgery, 2004, 78, 267-272.	0.7	42
35	Predictors and Prevalence of Latent Tuberculosis Infection in Patients Receiving Long-Term Hemodialysis and Peritoneal Dialysis. PLoS ONE, 2012, 7, e42592.	1.1	42
36	Use of High-Dose Inhaled Corticosteroids is Associated With Pulmonary Tuberculosis in Patients With Chronic Obstructive Pulmonary Disease. Medicine (United States), 2010, 89, 53-61.	0.4	40

#	Article	IF	CITATIONS
37	Performance assessment of the Capilia TB assay and the BD ProbeTec ET system for rapid culture confirmation of Mycobacterium tuberculosis. Diagnostic Microbiology and Infectious Disease, 2007, 59, 395-399.	0.8	39
38	Mycobacterium tuberculosis inducing disseminated intravascular coagulation. Thrombosis and Haemostasis, 2005, 93, 729-734.	1.8	36
39	Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan. Tuberculosis, 2018, 111, 121-126.	0.8	36
40	Attenuation of lymphocyte immune responses during Mycobacterium avium complex-induced lung disease due to increasing expression of programmed death-1 on lymphocytes. Scientific Reports, 2017, 7, 42004.	1.6	34
41	Nontuberculous mycobacteria pulmonary infection in medical intensive care unit: the incidence, patient characteristics, and clinical significance. Intensive Care Medicine, 2008, 34, 2194-2201.	3.9	33
42	Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy. Lung Cancer, 2013, 82, 420-425.	0.9	33
43	Treatment delay and fatal outcomes of pulmonary tuberculosis in advanced age: a retrospective nationwide cohort study. BMC Infectious Diseases, 2017, 17, 449.	1.3	33
44	SP110b Controls Host Immunity and Susceptibility to Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 369-382.	2.5	31
45	Metformin use is associated with a low risk of tuberculosis among newly diagnosed diabetes mellitus patients with normal renal function: A nationwide cohort study with validated diagnostic criteria. PLoS ONE, 2018, 13, e0205807.	1.1	30
46	High serum levels of procalcitonin and soluble TREM-1 correlated with poor prognosis in pulmonary tuberculosis. Journal of Infection, 2014, 68, 440-447.	1.7	29
47	Integrated postdischarge transitional care in a hospitalist system to improve discharge outcome: an experimental study. BMC Medicine, 2011, 9, 96.	2.3	28
48	Diagnostic role of inflammatory and antiâ€inflammatory cytokines and effector molecules of cytotoxic <scp>T</scp> lymphocytes in tuberculous pleural effusion. Respirology, 2015, 20, 147-154.	1.3	28
49	Clinical significance of isolation of nontuberculous mycobacteria in pulmonary tuberculosis patients. Respiratory Medicine, 2009, 103, 1484-1491.	1.3	27
50	Factors Associated with Lung Function Decline in Patients with Non-Tuberculous Mycobacterial Pulmonary Disease. PLoS ONE, 2013, 8, e58214.	1.1	27
51	Increased Risk of Active Tuberculosis following Acute Kidney Injury: A Nationwide, Population-Based Study. PLoS ONE, 2013, 8, e69556.	1.1	27
52	Plasma Biomarkers Can Predict Treatment Response in Tuberculosis Patients. Medicine (United States), 2015, 94, e1628.	0.4	26
53	Lower gastrointestinal tract tuberculosis: an important but neglected disease. International Journal of Colorectal Disease, 2009, 24, 1175-1180.	1.0	25
54	Sero-Diagnosis of Mycobacterium avium Complex Lung Disease Using Serum Immunoglobulin A Antibody against Glycopeptidolipid Antigen in Taiwan. PLoS ONE, 2013, 8, e80473.	1.1	24

#	Article	IF	CITATIONS
55	CD8 response measured by QuantiFERON-TB Gold Plus and tuberculosis disease status. Journal of Infection, 2019, 78, 299-304.	1.7	24
56	Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study. BMC Cancer, 2018, 18, 401.	1.1	23
57	Post-tuberculosis incidence of diabetes, myocardial infarction, and stroke: Retrospective cohort analysis of patients formerly treated for tuberculosis in Taiwan, 2002–2013. International Journal of Infectious Diseases, 2019, 84, 127-130.	1.5	23
58	Autoantibody prevalence in active tuberculosis: reactive or pathognomonic?. BMJ Open, 2013, 3, e002665.	0.8	22
59	Comparison of the Prevalence of Latent Tuberculosis Infection among Non-Dialysis Patients with Severe Chronic Kidney Disease, Patients Receiving Dialysis, and the Dialysis-Unit Staff: A Cross-Sectional Study. PLoS ONE, 2015, 10, e0124104.	1.1	22
60	Factors associated with subsequent nontuberculous mycobacterial lung disease in patients with a single sputum isolate on initial examination. Clinical Microbiology and Infection, 2015, 21, 250.e1-250.e7.	2.8	21
61	Tuberculosis contact investigation in an intermediate burden setting: implications from a large tuberculosis contact cohort in Taiwan. European Respiratory Journal, 2017, 50, 1700851.	3.1	21
62	The Clinical Significance of Programmed Death-1, Regulatory T Cells and Myeloid Derived Suppressor Cells in Patients with Nontuberculous Mycobacteria-Lung Disease. Journal of Clinical Medicine, 2019, 8, 736.	1.0	21
63	Dynamic changes in positive interferon-gamma release assay in a dialysis population: An observational cohort study. Journal of Infection, 2013, 67, 529-535.	1.7	20
64	Inhaled Corticosteroids Increase the Risk of Pneumonia in Patients With Chronic Obstructive Pulmonary Disease. Medicine (United States), 2015, 94, e1723.	0.4	20
65	<i>SP110</i> Polymorphisms Are Genetic Markers for Vulnerability to Latent and Active Tuberculosis Infection in Taiwan. Disease Markers, 2018, 2018, 1-12.	0.6	20
66	Completion Rate and Safety of Programmatic Screening and Treatment for Latent Tuberculosis Infection in Elderly Patients With Poorly Controlled Diabetic Mellitus: A Prospective Multicenter Study. Clinical Infectious Diseases, 2021, 73, e1252-e1260.	2.9	20
67	Nationwide Longitudinal Analysis of Acute Liver Failure in Taiwan. Medicine (United States), 2014, 93, e35.	0.4	20
68	Performance Assessment of the DR. MTBC Screen Assay and the BD ProbeTec ET System for Direct Detection of Mycobacterium tuberculosis in Respiratory Specimens. Journal of Clinical Microbiology, 2006, 44, 716-719.	1.8	19
69	Interferon-gamma release assay and Rifampicin therapy for household contacts of tuberculosis. Journal of Infection, 2012, 64, 291-298.	1.7	19
70	Apoptosis-associated biomarkers in tuberculosis: promising for diagnosis and prognosis prediction. BMC Infectious Diseases, 2013, 13, 45.	1.3	19
71	Risk Factors of Pneumothorax after CT-Guided Coaxial Cutting Needle Lung Biopsy through Aerated versus Nonaerated Lung. Journal of Vascular and Interventional Radiology, 2014, 25, 1209-1217.	0.2	19
72	Gender-Based Impact of Epidermal Growth Factor Receptor Mutation in Patients With Nonsmall Cell Lung Cancer and Previous Tuberculosis. Medicine (United States), 2015, 94, e444.	0.4	19

#	Article	IF	CITATIONS
73	Male Sex Is Associated With Worse Microbiological and Clinical Outcomes Following Tuberculosis Treatment: A Retrospective Cohort Study, a Systematic Review of the Literature, and Meta-analysis. Clinical Infectious Diseases, 2021, 73, 1580-1588.	2.9	18
74	Cytological Diagnosis of Penicillium marneffei Infection. Journal of the Formosan Medical Association, 2008, 107, 443-447.	0.8	16
75	Quantitative determination of isoniazid in biological samples by cation-selective exhaustive injection–sweeping–micellar electrokinetic chromatography. Analytical and Bioanalytical Chemistry, 2011, 401, 2205-2214.	1.9	16
76	Empirical use of fluoroquinolones improves the survival of critically ill patients with tuberculosis mimicking severe pneumonia. Critical Care, 2012, 16, R207.	2.5	16
77	Health system delay among patients with tuberculosis in Taiwan: 2003–2010. BMC Infectious Diseases, 2015, 15, 491.	1.3	16
78	Use of Antiplatelet Agents and Survival of Tuberculosis Patients: A Population-Based Cohort Study. Journal of Clinical Medicine, 2019, 8, 923.	1.0	16
79	Seroprevalence of Aspergillus IgG and disease prevalence of chronic pulmonary aspergillosis in a country with intermediate burden of tuberculosis: a prospective observational study. Clinical Microbiology and Infection, 2020, 26, 1091.e1-1091.e7.	2.8	16
80	Survival After Treatable Hepatocellular Carcinoma Recurrence in Liver Recipients: A Nationwide Cohort Analysis. Frontiers in Oncology, 2020, 10, 616094.	1.3	16
81	Spatial Dependency of Tuberculosis Incidence in Taiwan. PLoS ONE, 2012, 7, e50740.	1.1	15
82	Risk factors for Mycobacterium chelonae-abscessus pulmonary disease persistence and deterioration. Journal of Infection, 2012, 64, 228-230.	1.7	15
83	Risk of Tuberculosis Among Patients on Dialysis. Medicine (United States), 2016, 95, e3813.	0.4	15
84	Outcome of stage IV cancer patients receiving in-hospital cardiopulmonary resuscitation: a population-based cohort study. Scientific Reports, 2019, 9, 9478.	1.6	15
85	Isoniazid Concentration and NAT2 Genotype Predict Risk of Systemic Drug Reactions during 3HP for LTBI. Journal of Clinical Medicine, 2019, 8, 812.	1.0	15
86	In-hospital outcome of patients with culture-confirmed tuberculous pleurisy: clinical impact of pulmonary involvement. BMC Infectious Diseases, 2011, 11, 46.	1.3	14
87	Effects of acute critical illnesses on the performance of interferon-gamma release assay. Scientific Reports, 2016, 6, 19972.	1.6	14
88	Decreased T helper 17 cells in tuberculosis is associated with increased percentages of programmed death ligand 1, T helper 2 and regulatory T cells. Respiratory Research, 2017, 18, 128.	1.4	14
89	Gefitinib or erlotinib in previously treated non–smallâ€cell lung cancer patients: a cohort study in Taiwan. Cancer Medicine, 2017, 6, 1563-1572.	1.3	13
90	Latent Tuberculosis Infection Increases in Kidney Transplantation Recipients Compared With Transplantation Candidates: A Neglected Perspective in Tuberculosis Control. Clinical Infectious Diseases, 2020, 71, 914-923.	2.9	13

#	Article	IF	CITATIONS
91	Increased prevalence of primary drugâ€resistant pulmonary tuberculosis in immunocompromised patients. Respirology, 2011, 16, 308-313.	1.3	12
92	Interleukin 23/interleukin 17 axis activated by Mycobacterium avium complex (MAC) is attenuated in patients with MAC-lung disease. Tuberculosis, 2018, 110, 7-14.	0.8	12
93	Mitochondrial DNA Variants in Patients with Liver Injury Due to Anti-Tuberculosis Drugs. Journal of Clinical Medicine, 2019, 8, 1207.	1.0	12
94	Tuberculosis in Healthcare Workers: A Matched Cohort Study in Taiwan. PLoS ONE, 2015, 10, e0145047.	1.1	12
95	Nine- to Twelve-Month Anti-Tuberculosis Treatment Is Associated with a Lower Recurrence Rate than 6–9-Month Treatment in Human Immunodeficiency Virus-Infected Patients: A Retrospective Population-Based Cohort Study in Taiwan. PLoS ONE, 2015, 10, e0144136.	1.1	11
96	Fluoroquinolone use delays tuberculosis treatment despite immediate mycobacteriology study. European Respiratory Journal, 2015, 46, 567-570.	3.1	11
97	NLRP3 inflammasome is attenuated in patients with Mycobacterium avium complex lung disease and correlated with decreased interleukin-11 ² response and host susceptibility. Scientific Reports, 2019, 9, 12534.	1.6	11
98	Outcome of patients with and poor prognostic factors for Mycobacterium kansasii-pulmonary disease. Respiratory Medicine, 2019, 151, 19-26.	1.3	11
99	Effect of β-Blocker in Treatment-NaÃ ⁻ ve Patients With Advanced Lung Adenocarcinoma Receiving First-Generation EGFR-TKls. Frontiers in Oncology, 2020, 10, 583529.	1.3	11
100	Higher Serum Cholesterol Levels Are Associated With Reduced Systemic Inflammation and Mortality During Tuberculosis Treatment Independent of Body Mass Index. Frontiers in Cardiovascular Medicine, 2021, 8, 696517.	1.1	11
101	The association of atherosclerotic cardiovascular disease and statin use with inflammation and treatment outcomes in tuberculosis. Scientific Reports, 2021, 11, 15283.	1.6	11
102	Continuous lateral rotational therapy in the medical intensive care unit. Journal of the Formosan Medical Association, 2003, 102, 788-92.	0.8	10
103	Outcome Correlation of Smear-Positivity for Acid-Fast Bacilli at the Fifth Month of Treatment in Non-Multidrug–Resistant TB. Chest, 2013, 143, 1725-1732.	0.4	9
104	<scp><i>M</i></scp> <i>ycobacterium tuberculosis</i> nucleic acid amplification tests reduce nosocomial tuberculosis exposure in intensive care units: A nationwide cohort study. Respirology, 2015, 20, 1233-1240.	1.3	9
105	Clinical impact of using fluoroquinolone with low antimycobacterial activity on treatment delay in tuberculosis: Hospital-based and population-based cohort study. Journal of the Formosan Medical Association, 2020, 119, 367-376.	0.8	9
106	The Impact of Hypertension and Use of Calcium Channel Blockers on Tuberculosis Treatment Outcomes. Clinical Infectious Diseases, 2021, 73, e3409-e3418.	2.9	8
107	Impact of Age on Outcome of Rifapentine-Based Weekly Therapy for Latent Tuberculosis Infection. Clinical Infectious Diseases, 2021, 73, e1064-e1071.	2.9	8
108	The impact on incident tuberculosis by kidney function impairment status: analysis of severity relationship. Respiratory Research, 2020, 21, 51.	1.4	8

#	Article	IF	CITATIONS
109	Experience of applying threshold concepts in medical education. Journal of the Formosan Medical Association, 2021, 120, 1121-1126.	0.8	8
110	Circulatory Inflammatory Mediators in the Prediction of Anti-Tuberculous Drug-Induced Liver Injury Using RUCAM for Causality Assessment. Biomedicines, 2021, 9, 891.	1.4	8
111	Pre-class online video learning and class style expectation: patterns, association, and precision medical education. Annals of Medicine, 2021, 53, 1390-1401.	1.5	8
112	Unreliability of Pulse Contour-Derived Cardiac Output in Piglets Simulating Acute Hemorrhagic Shock and Rapid Volume Expansion. Journal of Trauma, 2010, 68, 1357-1361.	2.3	7
113	Predicting results of mycobacterial culture on sputum smear reversion after anti-tuberculous treatment: a case control study. BMC Infectious Diseases, 2010, 10, 48.	1.3	7
114	The trend and the disease prediction of vascular endothelial growth factor and placenta growth factor in nontuberculous mycobacterial lung disease. Scientific Reports, 2016, 6, 37266.	1.6	7
115	Predictors of developing Mycobacterium kansasii pulmonary disease within 1 year among patients with single isolation in multiple sputum samples: A retrospective, longitudinal, multicentre study. Scientific Reports, 2018, 8, 17826.	1.6	7
116	Association of Metformin Use With End‣tage Renal Disease in Patients With Type 2 Diabetes Mellitus: A Nationwide Cohort Study Under the Payâ€forâ€Performance Program. Journal of Clinical Pharmacology, 2019, 59, 1443-1452.	1.0	7
117	Impact of metformin use among tuberculosis close contacts with diabetes mellitus in a nationwide cohort study. BMC Infectious Diseases, 2019, 19, 936.	1.3	7
118	Curiosity in Online Video Concept Learning and Short-Term Outcomes in Blended Medical Education. Frontiers in Medicine, 2021, 8, 772956.	1.2	7
119	Active Tuberculosis During Temsirolimus and Bevacizumab Treatment. Journal of Clinical Oncology, 2013, 31, e18-e20.	0.8	6
120	Inflammatory markers and clinical characteristics for predicting persistent positivity of interferon gamma release assay in dialysis population. Scientific Reports, 2016, 6, 34577.	1.6	6
121	Gefitinib or Erlotinib for Previously Treated Lung Adenocarcinoma: Which Is Superior?. Journal of Clinical Oncology, 2017, 35, 1374-1375.	0.8	6
122	Outcome of untreated lung nodules with histological but no microbiological evidence of tuberculosis. BMC Infectious Diseases, 2018, 18, 530.	1.3	6
123	Acute biliary events during anti-tuberculosis treatment: hospital case series and a nationwide cohort study. BMC Infectious Diseases, 2018, 18, 64.	1.3	6
124	Efficient undergraduate learning of liver transplant: building a framework for teaching subspecialties to medical students. BMC Medical Education, 2018, 18, 161.	1.0	6
125	Differed IL-1 Beta Response between Active TB and LTBI Cases by Ex Vivo Stimulation of Human Monocyte-Derived Macrophage with TB-Specific Antigen. Disease Markers, 2019, 2019, 1-10.	0.6	6
126	Novel Short-Course Therapy and Morphism Mapping for Clinical Pulmonary Mycobacterium kansasii. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	6

#	Article	IF	CITATIONS
127	Establishing Aspergillus-Specific IgG Cut-Off Level for Chronic Pulmonary Aspergillosis Diagnosis: Multicenter Prospective Cohort Study. Journal of Fungi (Basel, Switzerland), 2021, 7, 480.	1.5	6
128	Disease Progression in Patients With Nontuberculous Mycobacterial Lung Disease of Nodular Bronchiectatic (NB) Pattern: The Roles of Cavitary NB and Soluble Programmed Death Protein-1. Clinical Infectious Diseases, 2022, 75, 239-247.	2.9	6
129	The impact of diabetes mellitus and its control on the development of tuberculosis: a nationwide longitudinal study in Taiwan. Pharmacoepidemiology and Drug Safety, 2013, 22, 995-1003.	0.9	5
130	Lung cancer mimicking pulmonary tuberculosis in a TB-endemic country: the role of early invasive diagnostic procedures. Lung Cancer Management, 2015, 4, 9-16.	1.5	5
131	The assessment of host and bacterial proteins in sputum from active pulmonary tuberculosis. Journal of Microbiology, 2016, 54, 761-767.	1.3	5
132	Predictors of radiographic progression for NTM–pulmonary disease diagnosed by bronchoscopy. Respiratory Medicine, 2020, 161, 105847.	1.3	5
133	The application of ultrasound shear wave elastography in the prediction of paradoxical upgrading reaction in tuberculous lymphadenitis. a pilot study. Journal of the Formosan Medical Association, 2022, 121, 1696-1704.	0.8	5
134	Prognostic value of the mitogen response in the interferon-Î ³ release assay in patients with culture-confirmed tuberculosis. Respiratory Medicine, 2019, 158, 49-54.	1.3	4
135	CD4 response of QuantiFERON-TB Cold Plus for positive consistency of latent tuberculosis infection in patients on dialysis. Scientific Reports, 2020, 10, 21367.	1.6	4
136	Completion and Adverse Drug Events of Latent Tuberculosis Infection Treatment in Patients Receiving Dialysis: Predictors and Impacts of Different Regimens in a Prospective Cohort Study. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	4
137	Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort. Frontiers in Oncology, 2020, 10, 590356.	1.3	4
138	Whole-Blood 3-Gene Signature as a Decision Aid for Rifapentine-based Tuberculosis Preventive Therapy. Clinical Infectious Diseases, 2022, 75, 743-752.	2.9	4
139	Nontraumatic pneumocephalus due to nosocomial Enterobacter cloacae infection. Diagnostic Microbiology and Infectious Disease, 2010, 66, 108-110.	0.8	3
140	Surgical resection is sufficient for incidentally discovered solitary pulmonary nodule caused by nontuberculous mycobacteria in asymptomatic patients. PLoS ONE, 2019, 14, e0222425.	1.1	3
141	Mono- and poly-functional T cells in nontuberculous mycobacteria lung disease patients: Implications in analyzing risk of disease progression. Cytokine, 2019, 120, 176-185.	1.4	3
142	Performance of Nucleic Acid Amplification Tests in Patients with Presumptive Pulmonary Tuberculosis in Taiwan. Infectious Diseases and Therapy, 2022, 11, 871-885.	1.8	3
143	Rifampin Pharmacokinetics/Pharmacodynamics in the Hollow-Fiber Model of Mycobacterium kansasii Infection. Antimicrobial Agents and Chemotherapy, 2022, 66, e0232021.	1.4	3
144	Influence of Pressure Control Levels on the Pulse Pressure Variations. Shock, 2011, 36, 628-632.	1.0	2

#	Article	IF	CITATIONS
145	Reply to S. Vale. Journal of Clinical Oncology, 2013, 31, 2634-2635.	0.8	2
146	Improving tuberculosis diagnostics with biomarkers. Current Biomarker Findings, 2015, , 13.	0.4	2
147	Abuse-related trauma forward medical care in a randomly sampled nationwide population. Medicine (United States), 2016, 95, e5214.	0.4	2
148	Highly Engaged Video-Watching Pattern in Asynchronous Online Pharmacology Course in Pre-clinical 4th-Year Medical Students Was Associated With a Good Self-Expectation, Understanding, and Performance. Frontiers in Medicine, 2021, 8, 799412.	1.2	2
149	Nucleic acid amplification tests reduce delayed diagnosis and misdiagnosis of pulmonary tuberculosis. Scientific Reports, 2022, 12, .	1.6	2
150	Isoniazid-resistant tuberculosis treatment with first-line drugs. Lancet Infectious Diseases, The, 2017, 17, 259-260.	4.6	1
151	Impact of introducing fluorescent microscopy on hospital tuberculosis control: A before-after study at a high caseload medical center in Taiwan. PLoS ONE, 2020, 15, e0230067.	1.1	1
152	Does a rifamycin-containing preventive regimen increase rifampicin resistance? An unresolved concern. International Journal of Tuberculosis and Lung Disease, 2016, 20, 998-998.	0.6	1
153	Subsequent Antituberculous Treatment may not be Mandatory among Surgically Resected Culture-Negative Pulmonary Granulomas: a Retrospective Nationwide Multicenter Cohort Study. Open Forum Infectious Diseases, 2021, 8, ofab565.	0.4	1
154	Advantages of Short-Course Rifamycin-based Regimens for Latent Tuberculosis Infection: An Updated Network Meta-Analysis. Journal of Global Antimicrobial Resistance, 2022, , .	0.9	1
155	Cooley's anemia. European Journal of Haematology, 2009, 82, 408-409.	1.1	0
156	Pulse Pressure Power Spectrum Predicts Volume Responsiveness in Shock Patients without Sedation. Shock, 2009, 33, 1.	1.0	0
157	Chasing Down the Acid-Fast Bacilli During Treatment: Response. Chest, 2013, 144, 1423-1424.	0.4	0
158	Time to be familiar with nontuberculous mycobacterial lung disease - An emerging disease with diverse clinical outcomes. Journal of the Formosan Medical Association, 2020, 119, S1-S3.	0.8	0
159	Successful treatment of a critical COVID-19 patient with tocilizumab. Journal of the Formosan Medical Association, 2021, 120, 1276-1278.	0.8	0
160	Reply to author. Clinical Infectious Diseases, 2021, , .	2.9	0
161	Non-tuberculous mycobacterial lung disease and COPD. , 0, , 172-184.		0

#	Article	IF	CITATIONS
163	Title is missing!. , 2019, 14, e0222425.		0
164	Title is missing!. , 2019, 14, e0222425.		0
165	Title is missing!. , 2019, 14, e0222425.		0
166	Title is missing!. , 2020, 15, e0230067.		0
167	Title is missing!. , 2020, 15, e0230067.		0
168	Title is missing!. , 2020, 15, e0230067.		0
169	Title is missing!. , 2020, 15, e0230067.		0
170	Bisphosphonate Use Is Not Associated with Tuberculosis Risk Among Patients With Osteoporosis: A Nationwide Cohort Study. Journal of Clinical Pharmacology, 0, , .	1.0	0